Polysomnography in Drug Development
- 1 January 1997
- journal article
- review article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 37 (S1) , 70S-78S
- https://doi.org/10.1177/009127009703700125
Abstract
Polysomnography in drug development is used to detect desirable and undesirable effects of drugs on normal and disturbed sleep. Although this method is essential for the approval of new hypnotic drugs, it is quite often neglected in the development of drugs that show unwanted side effects on normal sleep. In this review, the requirements for qualified polysomnography are described, the strong and weak points of the method are discussed, and its importance for the drug development process is pointed out.Keywords
This publication has 52 references indexed in Scilit:
- Empfehlungen zur Durchführung und Auswertung polygraphischer Ableitungen im diagnostischen SchlaflaborKlinische Neurophysiologie, 1993
- Sleep disorders. Steroids cause sleep disturbance.BMJ, 1993
- Hallucinations as an adverse effect of angiotensin converting enzyme inhibitionPublished by Oxford University Press (OUP) ,1993
- Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performanceClinical Cardiology, 1992
- Multiple Sleep Latency TestJournal Of Clinical Neurophysiology, 1992
- The Effect of Trimipramine on Sleep in Patients with Major Depressive DisorderPharmacopsychiatry, 1986
- Theophylline delays human sleep phaseLife Sciences, 1984
- ANTIHISTAMINES AND SEDATIONThe Lancet, 1983
- Early Morning Insomnia with Rapidly Eliminated BenzodiazepinesScience, 1983
- EVALUATION of SHORT-TERM and LONG-TERM TREATMENT of the NARCOLEPSY SYNDROME WITH CLOMIPRAMINE HYDROCHLORIDEActa Neurologica Scandinavica, 1976